1. A new synthetic resorcinolic lipid 3-Heptyl-3,4,6-trimethoxy-3H-isobenzofuran-1-one: Evaluation of toxicology and ability to potentiate the mutagenic and apoptotic effects of cyclophosphamide
- Author
-
Valdemar Lacerda Júnior, Antônio Carlos Duenhas Monreal, Adilson Beatriz, Alisson Meza, Stephanie Dynczuki Navarro, João Renato Pesarini, Andréa Luiza Cunha-Laura, Wanderson Romão, Caroline Bilhar Karaziack, Roberto da Silva Gomes, Mariana de Oliveira Mauro, and Rodrigo Juliano Oliveira
- Subjects
Male ,Side effect ,Cyclophosphamide ,Phagocytosis ,medicine.medical_treatment ,Antineoplastic Agents ,Apoptosis ,Pharmacology ,Transaminase ,Toxicology ,Mice ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Drug Discovery ,medicine ,Animals ,Immunologic Factors ,Chemotherapy ,Chemistry ,Organic Chemistry ,Resorcinols ,General Medicine ,Lipids ,Comet assay ,Comet Assay ,Micronucleus ,Mutagens ,medicine.drug - Abstract
Resorcinolic lipids have important biological actions, including anti-carcinogenic activity. Therefore, we evaluated the mutagenic, genotoxic, immunomodulatory and apoptotic potential and the biochemical and histopathological changes caused by the synthetic resorcinolic lipid 3-Heptyl-3,4,6-trimethoxy-3H-isobenzofuran-1-one, (AMS35AA; 10, 20 and 40 mg/kg) alone or in combination with cyclophosphamide (100 mg/kg) in Swiss mice. The results indicated that AMS35AA is not genotoxic or mutagenic and does not alter liver or kidney histology. However, the compound does cause an increase (p < 0.05) in the levels of glutamic-oxaloacetic transaminase and creatinine and in splenic phagocytosis and liver and kidney apoptosis. When combined with cyclophosphamide, AMS35AA caused increased (p < 0.05) mutagenic damage (although the compound had anti-genotoxic activity), splenic phagocytosis, neutropenia and glutamic-oxaloacetic transaminase and creatinine levels (even in the absence of histological damage) and induced liver and kidney apoptosis. We conclude that this resorcinolic lipid may be an important chemotherapy adjuvant that can potentiate mutagenic damage and increase apoptosis caused by cyclophosphamide without causing adverse effects. In addition, the immunomodulatory activity of the compound should be noted, which counters reductions in lymphocyte number, a primary side effect of cyclophosphamide in cancer therapy.
- Published
- 2014
- Full Text
- View/download PDF